Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

James R. Gavin, III net worth and biography

James Gavin, III Biography and Net Worth

Director of Baxter International

James R. Gavin, III, M.D., Ph.D. has served as a director of Baxter since 2003.

Dr. Gavin is chief executive officer and chief medical officer of Healing Our Village, Inc., a corporation that specializes in targeted advocacy, training, education, disease management, and outreach for health care professionals and minority communities. He previously served as executive vice president for clinical affairs at Healing Our Village from 2005 to 2007. Dr. Gavin is also clinical professor of medicine and senior advisor of health affairs at Emory University, a position he has held since 2005, and clinical professor of medicine at Indiana University School of Medicine in Indianapolis, a position he has held since 2008. From 2002 to 2005, Dr. Gavin was president of the Morehouse School of Medicine and from 1991 to 2002, he was senior science officer at Howard Hughes Medical Institute, a non-profit medical research organization. He previously served as a director of Amylin Pharmaceuticals, Inc. and Baxalta (before it was acquired by Shire in June 2016).

What is James R. Gavin, III's net worth?: The estimated net worth of James R. Gavin, III is at least $1.45 million as of August 3rd, 2020. Dr. Gavin, III owns 43,618 shares of Baxter International stock worth more than $1,448,554 as of November 22nd. This net worth evaluation does not reflect any other investments that Dr. Gavin, III may own. Learn More about James R. Gavin, III's net worth.
How do I contact James R. Gavin, III?: The corporate mailing address for Dr. Gavin, III and other Baxter International executives is One Baxter Parkway DF2-1W, Deerfield IL, 60015. Baxter International can also be reached via phone at (224) 948-2000 and via email at [email protected]. Learn More on James R. Gavin, III's contact information.
Has James R. Gavin, III been buying or selling shares of Baxter International?: James R. Gavin, III has not been actively trading shares of Baxter International during the last ninety days. Most recently, James R. Gavin III sold 14,899 shares of the business's stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $86.41, for a transaction totalling $1,287,422.59. Following the completion of the sale, the director now directly owns 43,618 shares of the company's stock, valued at $3,769,031.38. Learn More on James R. Gavin, III's trading history.
Who are Baxter International's active insiders?: Baxter International's insider roster includes Giuseppe Accogli (SVP), John Forsyth (Director), Andrew Frye (SVP), James Gavin, III (Director), Jacqueline Kunzler (SVP), Sean Martin (SVP), Jeanne Mason (SVP), Brian Stevens (CAO), and Albert Stroucken (Director). Learn More on Baxter International's active insiders.

James R. Gavin, III Insider Trading History at Baxter International

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/3/2020	Sell	14,899	$86.41	$1,287,422.59	43,618
8/19/2019	Sell	7,950	$87.63	$696,658.50	40,932
3/28/2018	Sell	18,750	$64.56	$1,210,500.00	36,398
3/29/2017	Sell	4,280	$51.72	$221,361.60	34,980
3/14/2016	Sell	5,660	$40.34	$228,324.40	33,432
4/27/2015	Sell	4,830	$71.06	$343,219.80
7/25/2013	Sell	5,760	$72.82	$419,443.20

James R. Gavin, III Buying and Selling Activity at Baxter International

Baxter International Company Overview

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Today's Range

Now: $33.21

$33.01

$33.70

50 Day Range

MA: $36.21

$31.71

$40.26

2 Week Range

Now: $33.21

$31.60

$44.01

Volume

4,640,657 shs

Average Volume

4,107,361 shs

Market Capitalization

$16.96 billion

P/E Ratio

166.06

Dividend Yield

3.57%

Beta

0.6

First JFK… next Elon?

From Porter & Company | Ad